New Two-Pronged attack on advanced sarcoma enters human trials
NCT ID NCT07460986
Summary
This study is testing whether adding a new antibody drug called bexmarilimab to a standard chemotherapy (doxorubicin) is safe and more effective for people with metastatic soft-tissue sarcoma. The trial will enroll about 278 adults who have not yet received doxorubicin for their advanced cancer. The main goals are to find the safest dose of the combination and to see if it can slow the cancer's progression better than standard treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARCOMA OF SOFT TISSUE are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.